Form SCHEDULE 13G Viking Therapeutics, Filed by: BlackRock, Inc.
Tweet
Share
E-mailSerious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Therapeutics starts Phase 1 trial of weight loss drug VK3019
- Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Create E-mail Alert Related Categories
SEC FilingsRelated Entities
13G, S3Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
